David, I had to read it a couple of times. My translation:
"A few years ago there was a study that showed a survival benefit of SRT, but it was mainly for men with rapid doubling times. Our study showed that there was indeed a survival benefit, but it is for both groups of men--those with doubling times less than 6 months and those with longer doubling times."
In other words, SRT conveys a statistical survival benefit, and it doesn't matter whether the PSADT was < or > than 6 months.
The previous study by Trock had surprised a lot of people, because in the past doctors had thought that rapid PSADT in the post-prostatectomy man was a strong indicator of distant disease, and therefore they might discourage men from SRT. Trock seemed to show that men with rapid doubling times were the ones who benefited the most, and the way most doctors interpreted that was due to the fact that rapid doubling times flagged men who were more likely to die of prostate cancer than with it. (Men with slow doubling times being more likely to live normal lifespans in spite of systemic PCa).
But here comes this new study, that showed at least at Duke, SRT conveys a survival benefit on a much larger group.
Dx Feb 2006, PSA 9 @age 43
RRP Apr 2006 - Gleason 3+4, T2c, NX MX, pos margins
PSA 5/06 <0.1, 8/06 0.2, 12/06 0.6, 1/07 0.7.
Salvage radiation (IMRT) Jan-Mar 2007
PSA 9/2007 and thereafter <0.1pcabefore50.blogspot.com